Auto stem cell transplant for lymphoma after chemo
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed non-Hodgkin lymphoma or Hodgkin lymphoma, and the lymphoma must be chemo-sensitive (not resistant).
- If your lymphoma is in partial or complete remission, you may qualify; if it is resistant, you usually will not.
- You must be able to do the study procedures with good overall strength (performance score mostly ≥ 80%; slightly lower may be allowed if the lymphoma causes it).
- Your blood, kidney, liver, heart, and lung tests must be strong enough for transplant treatment.
- You need to be well enough from recent treatment (at least 4 weeks since chemotherapy; specific longer timing for some drugs).
- You must not be pregnant or breastfeeding, and you must agree to birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
This Phase 2 study looks at a specific type of stem cell transplant that uses donor stem cells with immune cells removed, to treat certain high-risk leukemias and lymphomas. It aims to reduce relapse risk and improve outcomes in people who may need a transplant but have specific disease features.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.